Clarithromycin-Loaded Submicron-Sized Carriers: Pharmacokinetics and Pharmacodynamic Evaluation

Area of Science:

• Pharmaceutics
• Nanotechnology
• Infectious Diseases

Background:

• Complicated intra-abdominal infections pose significant therapeutic challenges.
• Improving antibiotic bioavailability and efficacy is crucial for effective management.
• Clarithromycin is a key antibiotic, but its delivery can be optimized.

Purpose of the Study:

• To develop and evaluate clarithromycin-loaded submicron dual lipid carriers (CLA-DLCs) for enhanced bioavailability and effectiveness.
• To assess the in vitro and in vivo performance of CLA-DLCs in managing intra-abdominal infections.
• To investigate the potential of CLA-DLCs in mitigating cytokine storm and oxidative stress.

Main Methods:

• Clarithromycin-loaded dual lipid carriers (CLA-DLCs) were prepared using a hot high shear homogenization technique.
• Characterization included colloidal parameters (size, zeta potential, entrapment efficiency), release profiles, and stability studies.
• In vitro antibiofilm activity, in vivo bioavailability, and therapeutic efficacy in a rat peritonitis model were evaluated.

Main Results:

• Optimized CLA-DLCs showed favorable colloidal properties (326.19 nm size, -31.34 mV zeta potential, 85.78% entrapment efficiency) and sustained release.
• CLA-DLCs demonstrated 3.43-fold higher in vitro anti-biofilm activity and a 5.89-fold increase in relative bioavailability compared to free clarithromycin.
• Treatment with CLA-DLCs significantly reduced microbial burden, oxidative stress, and inflammatory markers, improving survival in a rat peritonitis model.

Conclusions:

• CLA-DLCs represent a promising nanocarrier system for improving clarithromycin delivery.
• The developed CLA-DLCs show significant potential for managing intra-abdominal infections and preventing associated complications.
• This formulation offers enhanced therapeutic efficacy and reduced systemic toxicity compared to conventional clarithromycin administration.